1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Brain Tumor Report is to understand the market and pipeline status of the drugs around the Metastatic Brain Tumor to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Brain Tumor. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Metastatic Brain Tumor.
- A review of the marketed products under prescription for Metastatic Brain Tumor, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Metastatic Brain Tumor with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Metastatic Brain Tumor drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic Brain Tumor drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Brain Tumor drugs.
- Coverage of Metastatic Brain Tumor Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Metastatic Brain Tumor key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Metastatic Brain Tumor.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Brain Tumor.
- API intelligence over marketed drugs forMetastatic Brain Tumorand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Metastatic Brain Tumor.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Metastatic Brain Tumor
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Metastatic Brain Tumor
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Metastatic Brain Tumor
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Metastatic Brain Tumor Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Metastatic Brain Tumor Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Metastatic Brain Tumor Therapeutic Market, US, (Year), 2017
- Metastatic Brain Tumor Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Metastatic Brain Tumor Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Metastatic Brain Tumor Drugs, API Manufacturers, Europe by Country, 2017
- Metastatic Brain Tumor Drugs, API Manufacturers, India by State, 2017
- Metastatic Brain Tumor Drugs, API Manufacturers, China by Province, 2017
- Metastatic Brain Tumor Drugs, API Manufacturers by Geography 2017
- Metastatic Brain Tumor Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Metastatic Brain Tumor Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Metastatic Brain Tumor, 2017
- Discontinued Drugs for Metastatic Brain Tumor, 2017


List of Figures

- Metastatic Brain Tumor Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Metastatic Brain Tumor Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Metastatic Brain Tumor Therapeutic Market, US, (Year), 2017
- Metastatic Brain Tumor Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Metastatic Brain Tumor Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Metastatic Brain Tumor Drugs, API Manufacturers, Europe by Country, 2017
- Metastatic Brain Tumor Drugs, API Manufacturers, India by State, 2017
- Metastatic Brain Tumor Drugs, API Manufacturers, China by Province, 2017
- Metastatic Brain Tumor Drugs, API Manufacturers by Geography 2017
- Metastatic Brain Tumor Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Metastatic Brain Tumor Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Global Brain Tumor Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

Global Brain Tumor Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global brain tumor therapeutics market was estimated at USD XX million in 2015 and is expected to reach USD XX million by 2021, growing at a CAGR of X% during the forecast period 2016 to 2021. Brain ...

Global Glioblastoma Treatment Drugs Market Research Report 2016

Global Glioblastoma Treatment Drugs Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Glioblastoma Treatment Drugs Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Glioblastoma Treatment Drugs industry, focusing ...


Download Unlimited Documents from Trusted Public Sources

Endocrine Disease Statistics and Brain Cancer Statistics in the Netherlands

  • December 2016
    18 pages
  • Endocrine Disea...  

    Brain Cancer  

  • Netherlands  

View report >

Cancer Statistics in the US

  • December 2016
    74 pages
  • Cancer  

  • United States  

View report >

Brain Cancer Statistics

  • December 2016
    15 pages
  • Brain Cancer  

View report >

Cancer Statistics

3 months ago

Related Market Segments :

Brain Cancer
Cloud Computing

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.